PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
PAGE 14 (2005) Abstr 730 [www.page-meeting.org/?abstract=730]
T. Lehr (1), C. Tillmann (2), A. Staab (2), D. Trommeshauser (2), R. Binder (2), H.G. Schaefer (2), C. Kloft (1)
(1) Dept. Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (2) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a.d.R., Germany
Objectives & Background: Drug X is a new CNS active compound which is currently under clinical development. X inhibits the re-uptake transporter of the neurotransmitter W and is mainly metabolised to Y, which is the only metabolite found in human plasma. Y shows significant in vitro activity, but has never been administered to any species, so its pharmacokinetic (PK) properties and also the in vivo activity are unknown. In order to investigate the in vivo contribution of the metabolite to the observed pharmacodynamic (PD) effect an animal study was performed to determine the potency and effect-time course of drug X and metabolite Y.
Methods: Single doses of drug X or its metabolite Y were administered intravenously (0.3-10 mg/kg) or orally (1-20 mg/kg) to 132 female NMRI mice, 64 female NMRI mice were treated with placebo and served as control group. Samples for PK (X and Y) and PD were taken at 0.75, 1.5, 3, 16 and 17.5 h after administration. The PD effect was determined by the competitive inhibition of the re-uptake transporter of the neurotransmitter W by substance Z in mouse brain after administration of X or Y. Like X and Y, substance Z inhibits the re-uptake transporter W and was administered intravenously in a dose of 2.0 ÁCi as a tritium labelled molecule 45 minutes before the mice were decapitated. Selected areas of the mice brains were dissected and the amount of radioactivity per mg tissue was determined. Thus, the inhibition of the in vivo binding of drug X and metabolite Y by substance Z was determined. Overall, 197 plasma concentrations (65 drug X, 132 metabolite Y) and 132 PD measurements, from 132 mice, were available for developing the PK/PD model. The analyses were performed using the FO estimation method supplied by NONMEM version V, combined with graphical visualisation methods. Model development was performed in a sequential way, starting with a PK model for the metabolite after intravenous administration. Next, PK data from other administrations were added and the respective PK/PD models were built. The final model was to describe the complete PK/PD data of the 132 mice treated with drug X or Y.
Results: Plasma concentration-time profiles of drug X and metabolite Y were best described by one compartment models with saturable Michaelis-Menten (MM) elimination kinetics. Absorption of drug X after oral administration was best described by a first-order process combined with a MM process accounting for the first-pass metabolism. Absorption of Y could be modelled using a first-order absorption process. Metabolic formation of Y out of X was accounted for by a MM metabolism step. Volumes of distribution were found to be large with 17.7 L/kg (X) and 13.6 L/kg (Y) suggesting an extensive distribution into tissues. Within the linear PK range of X and Y, the parameters clearance and half-life could be derived from the estimated MM parameters. Clearances were found to be high with 5.3 L/h/kg (X) and 1.9 L/h/kg (Y) which resulted in half-lives of 2.3 h (X) and 4.9 h (Y), respectively.
Pharmacodynamic investigations revealed a 4.1 - 5.0 fold higher in vivo potency of drug X in comparison to metabolite Y regarding the inhibition of the neurotransmitter W re-uptake transporter in mice. Comparison of EC50 values of iv data and iv plus po data indicated that no additional active metabolites were built during the first-pass metabolism of drug X. Since under steady state conditions in humans plasma concentrations of the metabolite Y were approximately 3 fold lower than that of the parent compound X, and since the in vivo potency of Y is 5 fold lower the contribution of the active metabolite Y to the overall efficacy might be low.